BACKGROUND: The goal of this study was to develop an animal model of intestinal injury induced by 5-fluorouracil (5-FU) in pigs. METHODS: Six domestic pigs were used as control (healthy group) and another 6 malnourished pigs orally received 5-FU (treated group). After 4 weeks of treatment, pigs were sacrificed and jejunum, ileum and colon were isolated for histological, immunological and biochemical analyses. RESULTS: 5-FU caused a decrease in the intestinal mass. Disaccharidase, and phosphate alkaline activities, and glutathione redox cycle were disrupted by 5-FU. Histopathological alterations in the crypts and villous were greater in the small intestine than in the colon. 5-FU decreased the number of peripheral and intestinal leukocytes, promoting an increase in T-cytotoxic cells and a decrease in T-helper and B cells. CONCLUSION: This pig model of intestinal dysfunction closely mimics the common side effects of cancer chemotherapy in humans, and provides a useful tool for evaluating novel antimucotoxic agents. Copyright 2007 S. Karger AG, Basel.
BACKGROUND: The goal of this study was to develop an animal model of intestinal injury induced by 5-fluorouracil (5-FU) in pigs. METHODS: Six domestic pigs were used as control (healthy group) and another 6 malnourished pigs orally received 5-FU (treated group). After 4 weeks of treatment, pigs were sacrificed and jejunum, ileum and colon were isolated for histological, immunological and biochemical analyses. RESULTS:5-FU caused a decrease in the intestinal mass. Disaccharidase, and phosphate alkaline activities, and glutathione redox cycle were disrupted by 5-FU. Histopathological alterations in the crypts and villous were greater in the small intestine than in the colon. 5-FU decreased the number of peripheral and intestinal leukocytes, promoting an increase in T-cytotoxic cells and a decrease in T-helper and B cells. CONCLUSION: This pig model of intestinal dysfunction closely mimics the common side effects of cancer chemotherapy in humans, and provides a useful tool for evaluating novel antimucotoxic agents. Copyright 2007 S. Karger AG, Basel.
Authors: Jamee Martin; Scott C Howard; Asha Pillai; Peter Vogel; Anjaparavanda P Naren; Steven Davis; Karen Ringwald-Smith; Karyl Buddington; Randal K Buddington Journal: Chemotherapy Date: 2014-10-21 Impact factor: 2.544
Authors: Maria C E Andersen; Malene W Johansen; Thomas Nissen; Anders B Nexoe; Gunvor I Madsen; Grith L Sorensen; Uffe Holmskov; Anders Schlosser; Jesper B Moeller; Steffen Husby; Mathias Rathe Journal: Support Care Cancer Date: 2020-09-12 Impact factor: 3.603
Authors: Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2013-04-21 Impact factor: 3.603
Authors: Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2013-07-11 Impact factor: 3.603